Related Experiment Video
Updated: May 17, 2026
12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Optimal glycemic control in neurocritical care patients
Critical Care (London, England)
|October 31, 2012
Summary
Intensive insulin therapy for tight glycemic control in neurocritical care patients increases hypoglycemia risk. A moderate glucose target range (110-180 mg/dL) is recommended to improve neurological outcomes.
Area of Science:
- Neurocritical care
- Endocrinology
- Metabolic disorders
Background:
- Tight glycemic control (80-110 mg/dL) in neurocritical care is linked to increased hypoglycemia and no survival benefit.
- Hyperglycemia is associated with poorer neurological outcomes following acute brain injury.
Purpose of the Study:
- To recommend an updated glucose control strategy for neurocritical care patients.
- To address the risks of intensive insulin therapy and hypoglycemia.
Main Methods:
- Review of existing data on glycemic control in neurocritical care.
- Analysis of the relationship between hyperglycemia and neurological outcomes.
- Formulation of evidence-based recommendations.
Main Results:
- Intensive insulin therapy for tight glycemic control (80-110 mg/dL) leads to higher hypoglycemia rates without improving survival.
- Hyperglycemia correlates with worsened neurological outcomes after acute brain injury.
Conclusions:
- A moderate glucose target range (110-180 mg/dL) is recommended for neurocritical care patients.
- Recommendations include adequate nutrition, continuous insulin infusion (avoiding bolus), and careful glycemic monitoring.
Related Concept Videos
01:15Hypoglycemia and Glucagon
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:21Hyperosmolar Hyperglycemic State
Hyperosmolar Hyperglycemic State, or HHS, is a serious and life-threatening complication of type 2 diabetes mellitus. It is characterized by three main features: severe hyperglycemia, profound dehydration, and elevated serum osmolality, all occurring without significant ketoacidosis.HHS typically develops in older adults or individuals with limited access to fluids. This may result from illness, cognitive impairment, or medications such as diuretics or corticosteroids. These factors reduce...
01:25Diabetic Ketoacidosis l: Introduction
DefinitionDiabetic ketoacidosis (DKA) is an acute, life-threatening complication of diabetes mellitus, characterized by a triad of hyperglycemia (blood glucose >250 mg/dL), ketonemia or ketonuria, and metabolic acidosis (arterial pH <7.30 and serum bicarbonate <18 mEq/L). It results from insulin deficiency combined with elevated levels of counterregulatory hormones—glucagon, catecholamines, cortisol, and growth hormone—leading to increased lipolysis, hepatic ketone production, and...
01:22Diabetic Ketoacidosis ll: Pathophysiology
Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
01:26Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...